Fortrea Holdings Inc. (FTRE)
NASDAQ: FTRE · Real-Time Price · USD
5.46
-0.28 (-4.88%)
At close: Aug 1, 2025, 4:00 PM
5.76
+0.30 (5.49%)
After-hours: Aug 1, 2025, 7:30 PM EDT

Company Description

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum.

The company also offers delivery models that include full service, functional service provider, and hybrid service structures.

In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services.

Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines.

Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Fortrea Holdings Inc.
Fortrea Holdings logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees16,120
CEOPeter Neupert

Contact Details

Address:
8 Moore Drive
Durham, North Carolina 27709
United States
Phone877 495 0816
Websitefortrea.com

Stock Details

Ticker SymbolFTRE
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001965040
CUSIP Number34965K107
ISIN NumberUS34965K1079
Employer ID92-2796441
SIC Code8071

Key Executives

NamePosition
Peter M. NeupertInterim Chief Executive Officer, Chairman of the Board and Lead Independent Director
Jill McConnellChief Financial Officer
Mark A. MoraisChief Operating Officer and President of Clinical Services
Drayton VirklerPresident and Chief Commercial Officer
Robert ParksChief Accounting Officer
Alejandro Martinez GalindoChief Information Officer
Dave CooperChief Administrative Officer
Hima B. InguvaHead of Investor Relations and Corporate Development
J. Stillman Hanson J.D.General Counsel and Corporate Secretary
Dr. Oren J. Cohen M.D.Chief Medical Officer and President of Clinical Pharmacology

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 15, 2025SCHEDULE 13G/AFiling
Jun 12, 20258-KCurrent Report
Jun 12, 20258-A12BRegistration of securities
Jun 12, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report
Jun 3, 2025144Filing
Jun 3, 2025144Filing
Jun 3, 2025144Filing